TTrialPathMatch Me to Trials
← Back to trials
RecruitingGeneralized Anxiety Disorder

A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

Eligible age

18+ yrs

Accepts

All genders

Locations

13 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a global, phase 3, randomized, double-blind, parallel-group, 2-arm, placebo controlled, multicenter trial designed to compare the efficacy, safety and tolerability of a fixed dose of SEP-363856 (75 millligrams per day \[mg/day\]) to placebo over an 8-week double-blind treatment period in adults with generalized anxiety disorder (GAD).

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Where it's recruiting

Arizona

Phoenix

California

Los Angeles · Redlands · Sherman Oaks · Valley Village

Florida

Hallandale · Orlando

Massachusetts

Methuen · Watertown

New Jersey

Cherry Hill

New York

Jamaica · New York · The Bronx

Oklahoma

Oklahoma City

Oregon

Portland

Pennsylvania

Philadelphia

Tennessee

Memphis

Texas

Austin · Houston

Virginia

Fairfax

Source: ClinicalTrials.gov · NCT07767903 · last updated 2026-11-12

A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Ad · TrialPath